D
Douglas L. Dawley
Researcher at Harvard University
Publications - 6
Citations - 587
Douglas L. Dawley is an academic researcher from Harvard University. The author has contributed to research in topics: Pulmonary embolism & Tissue plasminogen activator. The author has an hindex of 6, co-authored 6 publications receiving 580 citations. Previous affiliations of Douglas L. Dawley include Veterans Health Administration & Beth Israel Deaconess Medical Center.
Papers
More filters
Journal ArticleDOI
Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism
Samuel Z. Goldhaber,John A. Heit,Gaurav Sharma,J. Stevan Nagel,Ducksoo Kim,J. Anthony Parker,D E Drum,Kathleen Reagan,James G. Anderson,Craig M. Kessler,John E. Markis,Douglas L. Dawley,Michael F. Meyerovitz,Douglas E. Vaughan,S S Tumeh,Joseph Loscalzo,Andrew P. Selwyn,Eugene Braunwald,Eugene Braunwald +18 more
TL;DR: In the dose regimens employed, rt-PA acts more rapidly and is safer than urokinase in the treatment of acute PE, and improvement in lung scan reperfusion at 24 h was identical in the two treatment groups.
Journal ArticleDOI
Acute pulmonary embolism treated with tissue plasminogen activator.
Samuel Z. Goldhaber,Samuel Z. Goldhaber,Samuel Z. Goldhaber,John E. Markis,John E. Markis,John E. Markis,Michael F. Meyerovitz,Michael F. Meyerovitz,Michael F. Meyerovitz,Ducksoo Kim,Ducksoo Kim,Ducksoo Kim,Douglas L. Dawley,Douglas L. Dawley,Douglas L. Dawley,Arthur A. Sasahara,Arthur A. Sasahara,Arthur A. Sasahara,Douglas E. Vaughan,Andrew P. Selwyn,Andrew P. Selwyn,Andrew P. Selwyn,Joseph Loscalzo,Joseph Loscalzo,Joseph Loscalzo,Craig M. Kessler,Craig M. Kessler,Craig M. Kessler,Gaurav Sharma,Gaurav Sharma,Gaurav Sharma,Elliott B. Grossbard,Elliott B. Grossbard,Elliott B. Grossbard,Eugene Braunwald,Eugene Braunwald,Eugene Braunwald +36 more
TL;DR: Recombinant human tissue-type plasminogen activator was given via a peripheral vein to 36 patients with angiographically documented pulmonary embolism and initial results make a case for expanded investigational use of peripheral intravenous rt-PA in pulmonary emblism.
Journal ArticleDOI
Thrombolytic therapy of acute pulmonary embolism: current status and future potential
Samuel Z. Goldhaber,Michael F. Meyerovitz,John E. Markis,Ducksoo Kim,Craig M. Kessler,Gaurav Sharma,Douglas E. Vaughan,Andrew P. Selwyn,Douglas L. Dawley,Joseph Loscalzo,Arthur A. Sasahara,Elliott B. Grossbard,Eugene Braunwald +12 more
TL;DR: The initial results demonstrate that, among selected patients, peripheral intravenous rt-PA can rapidly and, for the most part, safely lyse pulmonary embolism within 6 hours.
Journal ArticleDOI
Perspectives on treatment of acute pulmonary embolism with tissue plasminogen activator.
Samuel Z. Goldhaber,John E. Markis,Craig M. Kessler,Michael F. Meyerovitz,Ducksoo Kim,Vauchan De,Andrew P. Selwyn,Joseph Loscalzo,Douglas L. Dawley,Gaurav Sharma +9 more
Journal ArticleDOI
Tissue plasminogen activator and acute pulmonary embolism.
Samuel Z. Goldhaber,Craig M. Kessler,John A. Heit,John E. Markis,Gaurav Sharma,Gaurav Sharma,Douglas L. Dawley,Michael F. Meyerovitz,Douglas E. Vaughan,Douglas E. Vaughan,J. Anthony Parker,Patricia C. Come,Ducksoo Kim,Andrew P. Selwyn,Joseph Loscalzo,Eugene Braunwald +15 more
TL;DR: Among selected patients, peripheral intravenous rt‐PA is associated with rapid lysis of PE, improved pulmonary perfusion, and improved right ventricular function.